Once again, the science end at Zenith sounds great! Solid progress with lots of cookies in the oven! Couldn't be happier on this end of things!

Given all of that - and with the really positive talk of the potential partnership(s) - why in the world has the est. Enterprise Value taken such a direct hit?

And, why does management keep playing the role of a social worker to the corporate elite with these cheap financings at this advanced stage?

Just does not resonate with me!!!

2016 - A Clear Path Forward
Advanced Epigenetics Technology Creating Therapeutics for Oncology, Autoimmune & Animal Health Diseases

Founded
Corporate spin out from Resverlogix in June 2013
Status
Private – Considering a US market IPO
Cash Raised
2014/15
Approx. $19,500,000 @ $1.00 USD per share
Enterprise
Value est.
$110 MM
Shares Outstanding
99,042,045 shares outstanding
Approximately 111,000,000 fully diluted
Cash Burn
$1.6MM per quarter - Current

Corporate Update
September 12, 2018
Annual Meeting of Shareholders

Founded
Corporate spin out from Resverlogix in June 2013
Status
Private company, full reporting issuer
Cash Raised
2014
2018
US$50MM @ US$1.00 & US$2.00 per share
(all pre
clinical results based)

Shares
Outstanding
129.6MM
142.0MM
fully diluted
Cash Burn
$2MM per quarter
Current

Management’s Estimate of Fair Value of Common Shares
May 5, 2019
To whom it may concern,
Management’s estimate of the fair value of the common shares of Zenith Capital
Corp. for financial reporting purposes was USD $0.725 per share as at January
31, 2019.
If you require further information, please contact Sarah Zapotichny at
info@zenithepigenetics.com
(signed) “Brad Cann”
Brad Cann, CPA, CA, CBV.
Chief Financial Officer
Zenith Capital Corp.

Developing best and first in class combination therapies for oncology
June 18 th , 2020

Spun out of
Resverlogix in
June 2013
Private

Shares
Outstanding
(Diluted)
~145MM1